Bellevue Life Sciences Acquisition Corp.
BLAC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $4 | $2 | $0 | $0 |
| SG&A Expenses | $4 | $2 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4 | $2 | $0 | $0 |
| Operating Income | -$4 | -$2 | -$0 | -$0 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $3 | $0 | $0 |
| Pre-Tax Income | -$2 | $1 | -$0 | -$0 |
| Tax Expense | -$0 | $1 | $0 | $0 |
| Net Income | -$2 | $0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EPS | -0.54 | 0.072 | -0.004 | -0 |
| % Growth | -852.1% | 1,941% | -875% | – |
| EPS Diluted | -0.54 | 0.072 | -0.004 | -0 |
| Weighted Avg Shares Out | 4 | 8 | 9 | 8 |
| Weighted Avg Shares Out Dil | 4 | 8 | 9 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $3 | $0 | $0 |
| EBITDA | -$4 | $4 | $0 | $0 |
| % Margin | – | – | – | – |